CardioExchange Archive

December 1st, 2014

Selections from Richard Lehman’s Literature Review: December 1st

Richard Lehman, BM, BCh, MRCGP

This week’s topics include atenolol vs. losartan in children and young adults with Marfan’s syndrome, the Japanese Primary Prevention Project, and more.

---

November 18th, 2014

Losartan No Better Than Atenolol in Marfan’s Syndrome

Larry Husten, PHD

Beta-blockers have been the standard treatment for people with Marfan’s syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people. The goal of treatment is to prevent or slow down the dilation of the aorta and avoid aortic dissection, the main cause of death. In recent years, studies have raised the […]

---

September 2nd, 2013

Losartan Reduces Aortic Enlargement in Marfan Syndrome

Larry Husten, PHD

The COMPARE study provides the first confirmation that the angiotensin receptor blocker losartan reduces aortic enlargement in Marfan syndrome.

---

April 11th, 2012

Study Evaluates Losartan Efficacy in Heart Failure

Larry Husten, PHD

The angiotensin II-receptor blocker (ARB) losartan has labored under the perception that it is not as potent as other ARBs, and some evidence has suggested that it may not confer the same clinical benefits as other ARBs in heart failure patients. In a paper from Denmark published in JAMA, Henrik Svanström and colleagues performed a country-wide registry study […]

---

February 13th, 2012

Selections from Richard Lehman’s Weekly Review: Week of February 13th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include communicating with patients about screening and treatment and the association between blood-pressure-lowering drugs and gout.

---

January 11th, 2011

Candesartan Beats Losartan in Swedish HF Registry

Larry Husten, PHD

The Swedish Heart Failure Registry followed more than 5,000 patients treated with the angiotensin II receptor blockers (ARBs) candesartan or losartan between 2000 and 2009. According to a paper published in JAMA, survival at one year was 90% in the candesartan group compared to 83% in the losartan group. Five-year survival was 61% and 44%. […]

---